The upfront transaction is valued at around $2 billion, which is a 97% premium to the Canada-Boston biotech’s closing market price of $10.64 on Monday before the deal was announced.
Source link
AstraZeneca bets $2B on Canada-Boston biotech
La Potencia Mas Caliente